|
Balance Sheet Cash Flow Statement Archimedesweg 4-6 2333 CN Leiden, The Netherlands Tel. +31-71-519-91-01 Fax +31-71-519-98-00 |
Type: Public
On the web:
http://www.crucell.com
Employees:
1,126
Employee growth: 0.0%
Crucell wants to play a crucial role in drug development. The biotech firm develops, produces, and markets vaccines and antibodies to prevent and treat infectious diseases. The company currently markets vaccines, based on its PER.C6 technology, to protect against hepatitis A and B, influenza, and typhoid. It also licenses PER.C6 to other companies, including Merck and Sanofi-Aventis, for use in areas where Crucell has chosen not to work. Crucell's pipeline includes vaccine candidates for influenza, malaria, and rabies. The company has also contracted with the National Institutes of Health (NIH) to produce vaccines for the Ebola virus.
Key numbers for fiscal year ending December, 2008:
Sales: $399.3M
One year growth: 33.1%
Net income: $20.6M
Officers:
Chairman: Jan P. Oosterveld
President and CEO: Ronald H. P. Brus
COO: Cees de Jong
Competitors:
GSK Biologicals
Sanofi-Aventis
Vical
